Sign in
Taking people in United StatesPhase 1

First test of the new medicine NNC0113-5840 in people with overweight or obesity

Tests the safety of NNC0113-5840 in adults living with overweight or obesity.

Key facts

Who runs it
Novo Nordisk A/S
Where
Baltimore and Glendale, United StatesSee the 2 sites
Trial code
Registry title
A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity
Status
Recruiting
Phase
Phase 1
People taking part
48 people, planned
Started
1 May 2026
Expected to end
31 Jan 2027
Type of study
Interventional, 7 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • NNC0113-5840
  • Placebo
Record updated
9 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-55 who are overweight, with excess body fat, to test the safety of a new medicine, NNC0113-5840, against a placebo.

Age
18-55 years (both inclusive)
Sex
Men and women can join.
Disease stage
Overweight with a body mass index (BMI) between 25.0 and 34.9 kg/m2, due to excess body fat as judged by the investigator.

Main reasons for not taking part

  • Known or suspected allergy to the study medicine or related products
  • HbA1c of 6.5% (48 mmol/mol) or higher at screening
  • Any condition the investigator thinks could risk safety or following the study plan

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Male or female
  • Age 18-55 years (both inclusive) at the time of signing the informed consent
  • Body mass index (BMI) between 25.0 and 34.9 kilogram per meter square (kg/m2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit and visit 2, day -1, as judged by the investigator

Who cannot take part

  • Known or suspected hypersensitivity to study intervention(s) or related products
  • Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
  • Glycosylated haemoglobin (HbA1c) more than or equal to (≥) 6.5 percent (%) [48 millimole per mole (mmol/mol)] at screening

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

Where in United States

  • PAREXEL Intl - EPCU-BaltimoreBaltimore, United StatesContact: Novo NordiskTaking people
  • PAREXEL Glendale/LA EPCUGlendale, United StatesContact: Novo NordiskTaking people

About the trial

What the trial wants to find out

The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which treatment participants get is decided by chance.

The 7 groups in the trial

  • Cohort 1 NNC0113-5840Treatment being tested

    Participants will be randomized to receive NNC0113-5840 single dose level 1 subcutaneously.

    Treatment: NNC0113-5840

  • Cohort 2 NNC0113-5840Treatment being tested

    Participants will be randomized to receive NNC0113-5840 single dose level 2 subcutaneously.

    Treatment: NNC0113-5840

  • Cohort 3 NNC0113-5840Treatment being tested

    Participants will be randomized to receive NNC0113-5840 single dose level 3 subcutaneously.

    Treatment: NNC0113-5840

  • Cohort 4 NNC0113-5840Treatment being tested

    Participants will be randomized to receive NNC0113-5840 single dose level 4 subcutaneously.

    Treatment: NNC0113-5840

  • Cohort 5 NNC0113-5840Treatment being tested

    Participants will be randomized to receive NNC0113-5840 single dose level 5 subcutaneously.

    Treatment: NNC0113-5840

  • Cohort 6 NNC0113-5840Treatment being tested

    Participants will be randomized to receive NNC0113-5840 single dose level 6 subcutaneously.

    Treatment: NNC0113-5840

  • Placebo matching NNC0113-5840Placebo, for comparison

    Participants will receive placebo matched to NNC0113-5840 subcutaneously.

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A First in Human Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of NNC0113-5840 in Participants With Overweight or Obesity
Plain-language title
First test of the new medicine NNC0113-5840 in people with overweight or obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07566390, who can take part
Record updated
9 September 2026